These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 24217510)

  • 21. Mouse models of Alzheimer's disease: the long and filamentous road.
    Phinney AL; Horne P; Yang J; Janus C; Bergeron C; Westaway D
    Neurol Res; 2003 Sep; 25(6):590-600. PubMed ID: 14503012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tau-targeting therapies for Alzheimer disease.
    Congdon EE; Sigurdsson EM
    Nat Rev Neurol; 2018 Jul; 14(7):399-415. PubMed ID: 29895964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities.
    Tran HT; LaFerla FM; Holtzman DM; Brody DL
    J Neurosci; 2011 Jun; 31(26):9513-25. PubMed ID: 21715616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tau Proteins and Tauopathies in Alzheimer's Disease.
    Chong FP; Ng KY; Koh RY; Chye SM
    Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
    Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
    J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology.
    Isopi E; Granzotto A; Corona C; Bomba M; Ciavardelli D; Curcio M; Canzoniero LM; Navarra R; Lattanzio R; Piantelli M; Sensi SL
    Neurobiol Dis; 2015 Sep; 81():214-24. PubMed ID: 25434488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fuzhisan Ameliorates the Memory Deficits in Aged SAMP8 Mice via Decreasing Aβ Production and Tau Hyperphosphorylation of the Hippocampus.
    Zhang ZX; Zhao RP; Wang DS; Li YB
    Neurochem Res; 2016 Nov; 41(11):3074-3082. PubMed ID: 27518086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.
    Wisniewski T; Boutajangout A
    Brain Struct Funct; 2010 Mar; 214(2-3):201-18. PubMed ID: 20012091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer's Disease.
    Yin X; Qiu Y; Zhao C; Zhou Z; Bao J; Qian W
    Med Sci Monit; 2021 Sep; 27():e933084. PubMed ID: 34471085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Homocysteine exacerbates β-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles.
    Li JG; Chu J; Barrero C; Merali S; Praticò D
    Ann Neurol; 2014 Jun; 75(6):851-63. PubMed ID: 24644038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.
    Hurtado DE; Molina-Porcel L; Iba M; Aboagye AK; Paul SM; Trojanowski JQ; Lee VM
    Am J Pathol; 2010 Oct; 177(4):1977-88. PubMed ID: 20802182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.
    Oddo S; Billings L; Kesslak JP; Cribbs DH; LaFerla FM
    Neuron; 2004 Aug; 43(3):321-32. PubMed ID: 15294141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amyloid-β, tau, and the cholinergic system in Alzheimer's disease: seeking direction in a tangle of clues.
    Majdi A; Sadigh-Eteghad S; Rahigh Aghsan S; Farajdokht F; Vatandoust SM; Namvaran A; Mahmoudi J
    Rev Neurosci; 2020 May; 31(4):391-413. PubMed ID: 32017704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct Interaction between the β-Amyloid Core and Tau Facilitates Cross-Seeding: A Novel Target for Therapeutic Intervention.
    Tripathi T; Khan H
    Biochemistry; 2020 Feb; 59(4):341-342. PubMed ID: 31944100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice.
    Kocherhans S; Madhusudan A; Doehner J; Breu KS; Nitsch RM; Fritschy JM; Knuesel I
    J Neurosci; 2010 Jul; 30(27):9228-40. PubMed ID: 20610758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I; Hofer M; Friedman N
    J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review on Alzheimer's disease: Inhibition of amyloid beta and tau tangle formation.
    Ashrafian H; Zadeh EH; Khan RH
    Int J Biol Macromol; 2021 Jan; 167():382-394. PubMed ID: 33278431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The participation of insulin-like growth factor-binding protein 3 released by astrocytes in the pathology of Alzheimer's disease.
    Watanabe K; Uemura K; Asada M; Maesako M; Akiyama H; Shimohama S; Takahashi R; Kinoshita A
    Mol Brain; 2015 Dec; 8(1):82. PubMed ID: 26637371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased tauopathy drives microglia-mediated clearance of beta-amyloid.
    Chen W; Abud EA; Yeung ST; Lakatos A; Nassi T; Wang J; Blum D; Buée L; Poon WW; Blurton-Jones M
    Acta Neuropathol Commun; 2016 Jun; 4(1):63. PubMed ID: 27339073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble Conformers of Aβ and Tau Alter Selective Proteins Governing Axonal Transport.
    Sherman MA; LaCroix M; Amar F; Larson ME; Forster C; Aguzzi A; Bennett DA; Ramsden M; Lesné SE
    J Neurosci; 2016 Sep; 36(37):9647-58. PubMed ID: 27629715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.